

Arleigh McCurdy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6611131/publications.pdf>

Version: 2024-02-01

65
papers

2,005
citations

687363

13
h-index

243625

44
g-index

67
all docs

67
docs citations

67
times ranked

2832
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis. <i>Frontiers in Oncology</i> , 2022, 12, 826342.	2.8	3
2	Just the facts: how to diagnose and manage patients with multiple myeloma in the emergency department?. <i>Canadian Journal of Emergency Medicine</i> , 2022, 24, 256.	1.1	0
3	Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 608-617.	0.4	4
4	Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database. <i>Current Oncology</i> , 2022, 29, 1575-1582.	2.2	3
5	Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database. <i>British Journal of Haematology</i> , 2022, 198, 93-102.	2.5	3
6	When killers become thieves: Trogocytosed PD-1 inhibits NK cells in cancer. <i>Science Advances</i> , 2022, 8, eabj3286.	10.3	35
7	The impact of lenalidomide maintenance on secondâ€line chemotherapy in transplant eligible patients with multiple myeloma. <i>European Journal of Haematology</i> , 2021, 106, 673-681.	2.2	2
8	Realâ€world outcomes with bortezomibâ€containing regimens and lenalidomide plus dexamethasone for the treatment of transplantâ€ineligible multiple myeloma: a multiâ€institutional report from the Canadian Myeloma Research Group database. <i>British Journal of Haematology</i> , 2021, 193, 532-541.	2.5	9
9	Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the <sc>MCRN</sc>â€003/<sc>MYX</sc>.1 single arm phase <sc>II</sc> trial. <i>American Journal of Hematology</i> , 2021, 96, 552-560.	4.1	11
10	External validation of the FIRST trialâ€™s simplified frailty score in a population-based cohort. <i>Leukemia</i> , 2021, 35, 1823-1827.	7.2	9
11	Retrospective study of treatment patterns and outcomes postâ€lenalidomide for multiple myeloma in Canada. <i>European Journal of Haematology</i> , 2021, 107, 416-427.	2.2	4
12	The work of managing multiple myeloma and its implications for treatment-related decision making: a qualitative study of patient and caregiver experiences. <i>BMC Cancer</i> , 2021, 21, 793.	2.6	8
13	The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database. <i>Haematologica</i> , 2021, 106, 1733-1736.	3.5	11
14	P-222: Extended follow-up safety and efficacy results of Belantamab mafodotin (Belamaf) 1.92 mg/kg or 2.5 mg/kg combined with POM and DEX for the treatment of relapsed/refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S162.	0.4	0
15	Rivaroxaban for Improvement in Thromboembolism Outcomes in Patients with Multiple Myeloma on Lenalidomide-Based Therapy: The Rithmm Feasibility Pilot Trial. <i>Blood</i> , 2021, 138, 3232-3232.	1.4	1
16	Part 1 Results of a Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2021, 138, 1653-1653.	1.4	16
17	Lenalidomide Dosing and Outcomes in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database. <i>Blood</i> , 2021, 138, 4721-4721.	1.4	0
18	Maintenance therapy in transplant ineligible adults with newlyâ€diagnosed multiple myeloma: A systematic review and metaâ€analysis. <i>European Journal of Haematology</i> , 2020, 105, 626-634.	2.2	3

#	ARTICLE	IF	CITATIONS
19	The Evolving Field of Bone Imaging in Multiple Myeloma: Is it Time to Abandon Skeletal Surveys?. <i>Current Oncology</i> , 2020, 27, 10-11.	2.2	1
20	Anaplastic large cell lymphoma as a posttransplant lymphoproliferative disorder in a renal transplant patient: A case report. <i>EJHaem</i> , 2020, 1, 364-367.	1.0	1
21	Cyclophosphamide-Glucocorticoids versus Lenalidomide-Dexamethasone as Treatment for Multiple Myeloma at First Relapse after Autologous Stem Cell Transplantation – A Retrospective Analysis. <i>Hematology, Transfusion and Cell Therapy</i> , 2020, 43, 437-442.	0.2	0
22	Venous thromboembolic events in inflammatory bowel diseases: A review of current evidence and guidance on risk in the post-hospitalization setting. <i>Thrombosis Research</i> , 2020, 194, 26-32.	1.7	8
23	Is Tandem ASCT Needed in MM Patients with High Risk Cytogenetics in the Era of Maintenance Therapy? Results from the Canadian Myeloma Research Group (CMRG) Database. <i>Blood</i> , 2020, 136, 18-19.	1.4	1
24	A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 6-6.	1.4	2
25	Efficacy of Daratumumab Containing Regimens Post Lenalidomide Maintenance in Transplant Eligible Patients: Real-World Experience from the Canadian Myeloma Research Group Database. <i>Blood</i> , 2020, 136, 26-27.	1.4	1
26	Decision Making Factors That Influence Treatment Options for an Autologous Stem Cell Transplant for Older Adults (aged 65-75) with Newly Diagnosed Multiple Myeloma: A Mixed Methods Study. <i>Blood</i> , 2020, 136, 13-13.	1.4	1
27	Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database. <i>Blood</i> , 2020, 136, 5-7.	1.4	0
28	The impact of multiple myeloma induction therapy on hematopoietic stem cell mobilization and collection: 25-year experience. <i>Hematology, Transfusion and Cell Therapy</i> , 2019, 41, 285-291.	0.2	3
29	Health related quality of life for multiple myeloma patients according to treatment strategy after autologous stem cell transplant: a cross-sectional study using EORTC, EQ-5D and MY-20 scales. <i>Leukemia and Lymphoma</i> , 2019, 60, 1275-1282.	1.3	7
30	Are We Choosing Wisely With Autologous Hematopoietic Cell Transplantation Screening? The Utility of Pulmonary Function Testing Prior to Autologous Hematopoietic Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 68-72.	0.4	2
31	Overall and Progression Free Survival from the Mcrn-003/Myx.1 Trial: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma. <i>Blood</i> , 2019, 134, 1871-1871.	1.4	3
32	A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2019, 134, 3121-3121.	1.4	9
33	Treatment of Myeloma Patients Progressing on Lenalidomide-Based Maintenance after ASCT Performed As Part of 1st, 2nd or 3rd Line Therapy: Real-World Results from the National Myeloma Canada Research Network (MCRN) Database. <i>Blood</i> , 2019, 134, 3173-3173.	1.4	1
34	Bortezomib-Based Induction, Augmented Conditioning with Busulfan and Melphalan + ASCT and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma: Long-Term Results of the National Canadian Mcrn-001 Study. <i>Blood</i> , 2019, 134, 4570-4570.	1.4	1
35	Treatment of Multiple Myeloma Patients Progressing on Lenalidomide-Based Regimens. <i>Blood</i> , 2019, 134, 1886-1886.	1.4	1
36	Monoclonal protein reference change value as determined by gel-based serum protein electrophoresis. <i>Clinical Biochemistry</i> , 2018, 51, 61-65.	1.9	11

#	ARTICLE	IF	CITATIONS
37	Synoptic reporting for protein electrophoresis and immunofixation. <i>Clinical Biochemistry</i> , 2018, 51, 21-28.	1.9	12
38	MCRN003/MYX1: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma after 1-3 Prior Therapies. <i>Blood</i> , 2018, 132, 1984-1984.	1.4	1
39	Primary amyloidosis of the bladder; a mimicker of bladder cancer. <i>Canadian Journal of Urology</i> , 2017, 24, 8868-8870.	0.0	5
40	Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency. <i>Blood Coagulation and Fibrinolysis</i> , 2016, 27, 101-108.	1.0	9
41	Myelomatous Involvement of the Central Nervous System. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 644-654.	0.4	38
42	Amyloid Neuropathy Following Domino Liver Transplantation. <i>JAMA Neurology</i> , 2016, 73, 477.	9.0	4
43	Incidence and Risk Factors of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Agents. <i>Blood</i> , 2016, 128, 2624-2624.	1.4	9
44	Selinexor Shows Synergy in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma. <i>Blood</i> , 2016, 128, 3330-3330.	1.4	6
45	Myeloma Canada Research Network (MCRN)-001 ASCT Study of Busulfan + Melphalan (BuMel) Conditioning Followed By Lenalidomide (Len) Maintenance: Updated Results Including Serial Minimal Residual Disease (MRD) and Involved Serum Heavy Light Chain (HLC) Ratio Assessments. <i>Blood</i> , 2016, 128, 4632-4632.	1.4	1
46	Allogeneic Stem Cell Transplantation for Multiple Myeloma: a Single Center Experience. <i>Blood</i> , 2016, 128, 5874-5874.	1.4	1
47	Selinexor in Combination with Bortezomib and Dexamethasone (SdB) Demonstrates Significant Activity in Patients with Refractory Multiple Myeloma (MM) Including Proteasome-Inhibitor Refractory Patients: Results of the Phase I Stomp Trial. <i>Blood</i> , 2016, 128, 977-977.	1.4	15
48	Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience. <i>World Journal of Transplantation</i> , 2016, 6, 380.	1.6	56
49	A Comparison of Cyclophosphamide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2016, 128, 4519-4519.	1.4	1
50	Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both. <i>Leukemia and Lymphoma</i> , 2015, 56, 3357-3364.	1.3	36
51	Systemic mastocytosis emerging after azacitidine treatment of refractory anaemia with excess blasts type 2. <i>British Journal of Haematology</i> , 2014, 167, 147-147.	2.5	3
52	Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. <i>Leukemia</i> , 2014, 28, 1122-1128.	7.2	1,128
53	Smoldering multiple myeloma requiring treatment: time for a new definition?. <i>Blood</i> , 2013, 122, 4172-4181.	1.4	70
54	Long-term outcome of patients with multiple myeloma-related advanced renal failure following auto-SCT. <i>Bone Marrow Transplantation</i> , 2013, 48, 1543-1547.	2.4	30

#	ARTICLE	IF	CITATIONS
55	Coexistent Multiple Myeloma or Increased Bone Marrow Plasma Cells Define Equally High-Risk Populations in Patients With Immunoglobulin Light Chain Amyloidosis. <i>Journal of Clinical Oncology</i> , 2013, 31, 4319-4324.	1.6	193
56	Pomalidomide and its clinical potential for relapsed or refractory multiple myeloma: an update for the hematologist. <i>Therapeutic Advances in Hematology</i> , 2013, 4, 211-216.	2.5	19
57	Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2013, 31, 4529-4535.	1.6	147
58	Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. <i>Leukemia</i> , 2013, 27, 2062-2066.	7.2	30
59	Survival Outcomes Of Very Young (<40 years) Myeloma Patients. <i>Blood</i> , 2013, 122, 2136-2136.	1.4	3
60	Soluble ST2 (sST2) Is a Novel Valuable Prognostic Marker Among Patients With Immunoglobulin Light Chain (AL) Amyloidosis. <i>Blood</i> , 2013, 122, 3095-3095.	1.4	1
61	Myelomatous Involvement Of The Central Nervous System: Mayo Clinic Experience. <i>Blood</i> , 2013, 122, 3119-3119.	1.4	3
62	Autologous Stem Cell Transplantation In Immunoglobulin Light Chain Amyloidosis With Factor X Deficien. <i>Blood</i> , 2013, 122, 2151-2151.	1.4	9
63	Effect Of Immediate Prior-Line Lenalidomide Or Thalidomide Therapy On Response To Pomalidomide In Multiple Myeloma. <i>Blood</i> , 2013, 122, 1979-1979.	1.4	0
64	Long Term Response To Lenalidomide With and Without Continuous Therapy Among Patients With Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2013, 122, 3209-3209.	1.4	0
65	Wild-type ATTR amyloidosis of the prostate: a case review. <i>Journal of Clinical Urology</i> , 0, , 205141582110237.	0.1	0